Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
medac Gesellschaft für klinische Spezialpräparate mbH
ATC Code
L01AD01
Source
EMA · EMEA/H/C/004326
(
ARTG
)
Carmustine Lupin is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:,1. Malignant Glioma,2. Multiple Myeloma - in combination with prednisone.,3. Hodgkins Disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.,4. Non-Hodgkins lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.
⚠️ Warnings
• Avoid immunization while taking this medication.
• If you are taking any other medication, inform the doctor.
• Caution should be exercised in patients with history of liver or kidney impairment, decrease in blood count, bone marrow depression, lung disease, during pregnancy and breast-feeding.
• Monitor blood count, liver, kidney and lung function regularly while taking this medication.
• It may cause dizziness or drowsiness, do not drive a car or operate machinery while taking this medication.
